Redhill Biopharma shares surge 15.53% premarket as RHB-102 advances in GLP-1 therapy-related GI side effects.

RedHill Biopharma surged 15.53% in premarket trading following the announcement of significant progress for RHB-102 in multiple gastrointestinal (GI) indications, including its development via the accelerated FDA 505(b)(2) route as a potential treatment for GLP-1/GIP therapy-associated GI side effects. The news highlighted positive U.S. Phase 3 and Phase 2 results for gastroenteritis/gastritis and IBS-D, respectively, along with the drug’s potential to address a major barrier in the GLP-1 market, where up to 50% of patients discontinue therapy due to GI side effects. The company emphasized RHB-102’s de-risked profile, supported by decades of ondansetron clinical use and proprietary formulation, positioning it to reduce $35 billion in projected market losses by 2030. These developments, coupled with plans for a Phase 2 trial in GLP-1/GIP-related GI side effects, drove investor optimism about the drug’s commercial and regulatory potential.